Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID) Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | PharmaTher, Neurolixis, Bukwang Pharmaceutical, Vistagen Therapeutics, Adamas Pharmaceuticals,

DelveInsight's "Parkinson's Disease Levodopa-induced Dyskinesia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Parkinson's Disease Levodopa-induced Dyskinesia, historical and forecasted epidemiology as well as the Parkinson's Disease Levodopa-induced Dyskinesia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Parkinson's Disease Levodopa-induced Dyskinesia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson's Disease Levodopa-induced Dyskinesia Market Forecast
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Parkinson's Disease Levodopa-induced Dyskinesia Market Report:
• The Parkinson's Disease Levodopa-induced Dyskinesia market size was valued USD 1,487 milliion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2022, there were an estimated 2,349,278 diagnosed prevalent cases of Parkinson's disease in the 7MM. Projections anticipate a rise in these numbers by 2032 within the forecast period (2023─2032).
• In 2022, the disease's age-specific breakdown indicates that the majority of cases (66%) in Germany were among individuals aged ≥75 years, followed by those aged 65─74 years (19%). The lowest number of cases was observed in the age group of ≤49 years.
• In 2022, there were approximately 590,763 cases of PD-LID across the 7MM, with the United States reporting the highest number, trailed by Germany, France, and other countries. It is anticipated that these cases will rise during the projected period.
• In 2022, France contributed to around 9% of the PD-LID cases within the 7MM. Projections indicate an anticipated increase at a Compound Annual Growth Rate (CAGR) of approximately 0.8% by 2032.
• Key Parkinson's Disease Levodopa-induced Dyskinesia Companies: PharmaTher, Neurolixis, Bukwang Pharmaceutical, Vistagen Therapeutics, Adamas Pharmaceuticals, Inc., Novartis, EMD Serono, Avanir Pharmaceuticals, UCB Pharma, and others
• Key Parkinson's Disease Levodopa-induced Dyskinesia Therapies: KETARX(ketami ne), NLX-112/F13640(befiradol), JM-010, AV-101, ADS-5102, AFQ056, Sarizotan HCl, AVP-923-45, AFQ056, Levetiracetam, and others
• The Parkinson's Disease Levodopa-induced Dyskinesia epidemiology based on type-specific cases analyzed that there are three types of PD-LID: peak-dose dyskinesia, off period dystonia, and diphasic dyskinesia, among which peak-dose dyskinesia accounted for the highest number of cases, whereas diphasic dyskinesia for least during the forecast period.
• The Parkinson's Disease Levodopa-induced Dyskinesia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson's Disease Levodopa-induced Dyskinesia pipeline products will significantly revolutionize the Parkinson's Disease Levodopa-induced Dyskinesia market dynamics.

Parkinson's Disease Levodopa-induced Dyskinesia Overview
Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID) refers to a complication that arises in individuals with Parkinson's disease who are treated with levodopa medication. It manifests as abnormal, involuntary movements or dyskinesias, such as twisting, writhing, or jerking, which occur as a side effect of long-term use of levodopa therapy for managing Parkinson's symptoms.

Get a Free sample for the Parkinson's Disease Levodopa-induced Dyskinesia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology Segmentation:
The Parkinson's Disease Levodopa-induced Dyskinesia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Parkinson's Disease Levodopa-induced Dyskinesia
• Prevalent Cases of Parkinson's Disease Levodopa-induced Dyskinesia by severity
• Gender-specific Prevalence of Parkinson's Disease Levodopa-induced Dyskinesia
• Diagnosed Cases of Episodic and Chronic Parkinson's Disease Levodopa-induced Dyskinesia

Download the report to understand which factors are driving Parkinson's Disease Levodopa-induced Dyskinesia epidemiology trends @ Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology Forecast
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Levodopa-induced Dyskinesia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson's Disease Levodopa-induced Dyskinesia market or expected to get launched during the study period. The analysis covers Parkinson's Disease Levodopa-induced Dyskinesia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Parkinson's Disease Levodopa-induced Dyskinesia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Parkinson's Disease Levodopa-induced Dyskinesia Therapies and Key Companies
• KETARX(ketami ne): PharmaTher
• NLX-112/F13640(befiradol): Neurolixis
• JM-010: Bukwang Pharmaceutical
• AV-101: Vistagen Therapeutics
• ADS-5102: Adamas Pharmaceuticals, Inc.
• AFQ056: Novartis
• Sarizotan HCl: EMD Serono
• AVP-923-45: Avanir Pharmaceuticals
• AFQ056: Novartis
• Levetiracetam: UCB Pharma

Discover more about therapies set to grab major Parkinson's Disease Levodopa-induced Dyskinesia market share @ Parkinson's Disease Levodopa-induced Dyskinesia Treatment Landscape
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Parkinson's Disease Levodopa-induced Dyskinesia Market Drivers
• The concept of 'drug-repurposing' has been used in drug development for LID for many years, for instance, amantadine was initially licensed for viral infections, and clinical observation noted improved symptoms in PD subjects using the drug for influenza.
• The constant researches on novel AI-driven computational approaches and improvements in formulating long-acting LDOPA preparations or infusion systems offer means to drive drug discovery, which may further lower the incidence of LID.

Parkinson's Disease Levodopa-induced Dyskinesia Market Barriers
• The increasing prevalence of PD in the geriatric population offers a potential market to the key pharma players, as ~50% of PD patients on L-DOPA experience LID.
• Improvements in the measurement of LID may emerge from technological advances, for instance, a wearable device easily worn by the patient at home that provides a measure oflimb/trunk movement that correlates with LID level.

Scope of the Parkinson's Disease Levodopa-induced Dyskinesia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Parkinson's Disease Levodopa-induced Dyskinesia Companies: PharmaTher, Neurolixis, Bukwang Pharmaceutical, Vistagen Therapeutics, Adamas Pharmaceuticals, Inc., Novartis, EMD Serono, Avanir Pharmaceuticals, UCB Pharma, and others
• Key Parkinson's Disease Levodopa-induced Dyskinesia Therapies: KETARX(ketami ne), NLX-112/F13640(befiradol), JM-010, AV-101, ADS-5102, AFQ056, Sarizotan HCl, AVP-923-45, AFQ056, Levetiracetam, and others
• Parkinson's Disease Levodopa-induced Dyskinesia Therapeutic Assessment: Parkinson's Disease Levodopa-induced Dyskinesia current marketed and Parkinson's Disease Levodopa-induced Dyskinesia emerging therapies
• Parkinson's Disease Levodopa-induced Dyskinesia Market Dynamics: Parkinson's Disease Levodopa-induced Dyskinesia market drivers and Parkinson's Disease Levodopa-induced Dyskinesia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Parkinson's Disease Levodopa-induced Dyskinesia Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Levodopa-induced Dyskinesia Market Access and Reimbursement

To know more about Parkinson's Disease Levodopa-induced Dyskinesia companies working in the treatment market, visit @ Parkinson's Disease Levodopa-induced Dyskinesia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/parkinsons-disease-levodopa-induced-dyskinesia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Parkinson's Disease Levodopa-induced Dyskinesia Market Report Introduction
2. Executive Summary for Parkinson's Disease Levodopa-induced Dyskinesia
3. SWOT analysis of Parkinson's Disease Levodopa-induced Dyskinesia
4. Parkinson's Disease Levodopa-induced Dyskinesia Patient Share (%) Overview at a Glance
5. Parkinson's Disease Levodopa-induced Dyskinesia Market Overview at a Glance
6. Parkinson's Disease Levodopa-induced Dyskinesia Disease Background and Overview
7. Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology and Patient Population
8. Country-Specific Patient Population of Parkinson's Disease Levodopa-induced Dyskinesia
9. Parkinson's Disease Levodopa-induced Dyskinesia Current Treatment and Medical Practices
10. Parkinson's Disease Levodopa-induced Dyskinesia Unmet Needs
11. Parkinson's Disease Levodopa-induced Dyskinesia Emerging Therapies
12. Parkinson's Disease Levodopa-induced Dyskinesia Market Outlook
13. Country-Wise Parkinson's Disease Levodopa-induced Dyskinesia Market Analysis (2019-2032)
14. Parkinson's Disease Levodopa-induced Dyskinesia Market Access and Reimbursement of Therapies
15. Parkinson's Disease Levodopa-induced Dyskinesia Market Drivers
16. Parkinson's Disease Levodopa-induced Dyskinesia Market Barriers
17. Parkinson's Disease Levodopa-induced Dyskinesia Appendix
18. Parkinson's Disease Levodopa-induced Dyskinesia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-pd-lid-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Parkinson's Disease Levodopa-induced Dyskinesia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Parkinson's Disease Levodopa-induced Dyskinesia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Ischemia-reperfusion Injury Market https://www.delveinsight.com/report-store/ischemia-reperfusion-injury-market
DelveInsight's report titled "Ischemia-reperfusion injury Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes historical and projected epidemiological data concerning Ischemia-reperfusion injury. This analysis includes a breakdown of the Incident Cases of Ischemia-reperfusion injury, Organ-specific Incident Cases of Ischemia-reperfusion injury, Gender-specific Incident Cases of Ischemia-reperfusion Injury, and Age-specific Incident Cases of Ischemia-reperfusion Injury.

Meniscus Tear Market
https://www.delveinsight.com/report-store/meniscus-tear-market
DelveInsight's report titled "Meniscus Tear Market Insights, Epidemiology, and Market Forecast -2032" provides a comprehensive analysis of Meniscus Tear. The report includes a detailed examination of the historical and projected epidemiology data that includes Total Incident Cases of Meniscus Tear, Gender-specific Incident Cases of Meniscus Tear, Age-specific Incident Cases of Meniscus Tear, Treatable Cases of Meniscus Tear.

Functional Dyspepsia Market https://www.delveinsight.com/report-store/functional-dyspepsia-market-insights
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market
DelveInsight's report titled "Diphtheria Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes diphtheria. The report includes a detailed examination of the historical and projected epidemiology data that includes incident cases of diphtheria segmented by age and type.

Chronic Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
DelveInsight's report titled "Chronic Constipation Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Chronic constipation. The report includes a detailed examination of the historical and projected epidemiology data, including Total Prevalent Cases, Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, and Age-specific Diagnosed Prevalent cases of Chronic Constipation.

Pulmonary Fibrosis Market
https://www.delveinsight.com/report-store/pulmonary-fibrosis-market
DelveInsight's "Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.